Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature

Volume: 43, Issue: 1, Pages: 113 - 118
Published: Aug 1, 2013
Abstract
null Background null Glucocorticoids (GC) are the mainstay of treatment of null rheumatica (PMR). However GC-related adverse events occur frequently, particularly in patients with relapsing disease. Several studies have demonstrated that IL-6 is a key player in the pathogenesis of PMR. null Objectives null To report 2 patients with PMR treated with the anti-IL-6 receptor monoclonal antibody tocilizumab (TCZ) and to review the published evidence...
Paper Details
Title
Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature
Published Date
Aug 1, 2013
Volume
43
Issue
1
Pages
113 - 118
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.